1. Anti-obesity medications show improvements in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
2. Diagnostic challenges exist in assessing obesity in HFpEF patients.
3. Structured monitoring is advised during the initiation of anti-obesity medications.
4. Metabolic and bariatric surgery was discussed as a treatment option, with potential risks noted.
5. Evidence-based selection criteria for FDA-approved anti-obesity therapies were provided.

Source: Journal of the American College of Cardiology